From: The prognostic significance of tumour-stroma ratio in endometrial carcinoma
 | Overall survival | Disease-free survival | ||
---|---|---|---|---|
Factor | HR (95Â % CI) | P | HR (95Â % CI) | P |
TSR ( ≥1.30 vs. <1.30) | 1.18 (0.56–2.47) | 0.667 | 1.12 (0.57–2.18) | 0.740 |
Age (continuous) | 1.07 (1.05–1.09) | <0.001 | 1.06 (1.04–1.08) | <0.001 |
Stage (FIGO 2009) | Â | Â | Â | Â |
 I | Referent | Referent | Referent | Referent |
 II | 1.12 (0.60–2.09) | 0.731 | 1.10 (0.60–2.00) | 0.603 |
 III | 1.69 (1.07–2.67) | 0.024 | 1.64 (1.06–2.54) | 0.028 |
 IV | 8.38 (4.75–14.74) | <0.001 | 6.77 (3.92–11.70) | <0.001 |
Grade | Â | Â | Â | Â |
 1 | Referent | Referent | Referent | Referent |
 2 | 1.06 (0.61–1.86) | 0.835 | 0.95 (0.57–1.61) | 0.857 |
 3 | 1.96 (1.20–3.21) | 0.007 | 1.61 (1.02–2.55) | 0.042 |
Lymphovascular invasion (yes vs. no) | 1.94 (1.26–2.90) | 0.002 | 1.95 (1.30–2.94) | 0.001 |